Revolution Medicines Inc (RVMD)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Revolution Medicines Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 21 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 187.50 $ — 97% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 10.4% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 12
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -8.07 | -8.94 – -7.20 | 103 | -35.6% | 19 |
| 12/31/2027 | -5.80 | -10.74 – 0.96 | 881 | 28.1% | 17 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -1.93 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.16 | – | 262 | 35,155.00 | -74.40 | -138 | -140 |
| 2025: Q1 | -1.13 | – | 0 | – | – | -194 | -198 |
| 2025: Q2 | -1.32 | – | 0 | – | – | -222 | -229 |
| 2025: Q3 | -1.61 | – | 0 | – | – | -207 | -211 |
| 2025: Q4 | -1.92 | – | 0 | -100.00 | – | -274 | -276 |
| 2026: Q1 | -2.29 | – | 0 | – | – | -354 | -356 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | 0 | -31 | -31 | -0.85 | -25 | 5 | 15 |
| 2018 | 20 | -40 | -42 | -1.15 | 1 | 97 | 171 |
| 2019 | 50 | -54 | -48 | -1.31 | -50 | 153 | 221 |
| 2020 | 43 | -111 | -108 | -1.62 | -100 | 475 | 567 |
| 2021 | 29 | -188 | -187 | -2.57 | -147 | 603 | 738 |
| 2022 | 35 | -258 | -249 | -3.08 | -224 | 685 | 812 |
| 2023 | 12 | -487 | -436 | -3.86 | -351 | 1,826 | 2,062 |
| 2024 | 0 | -690 | -600 | -3.58 | -557 | 2,265 | 2,558 |
| 2025 | 0 | -1,182 | -1,131 | -5.95 | -898 | 1,631 | 2,355 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Revolution Medicines, Inc. ist ein Präzisionsonkologie-Unternehmen in der klinischen Phase, das neuartige zielgerichtete Therapien für RAS-abhängige Krebserkrankungen entwickelt.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 883 |
| Headquarters | Redwood City, CA |
| Address | 700 Saginaw Drive, 94063 Redwood City, United States |
| Phone | 650 481 6801 |
| Website | revmed.com |
| IPO Date | 13. Feb 2020 |
| ISIN | US76155X1000 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Mark A. Goldsmith M.D., Ph.D. | CEO, President & Chairman | 1962 |
| Jack Anders | Chief Financial Officer | 1977 |
| Margaret A. Horn J.D. | Chief Operating Officer | 1963 |
| Jeffrey Cislini J.D. | Senior VP, General Counsel & Corporate Secretary | 1975 |
| Stephen M. Kelsey FRC Path., FRCP, M.D. | Senior Advisor | 1961 |
| Martin D. Burke M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | – |
| Michael A. Fischbach Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | 1981 |
| Kevan M. Shokat Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | – |
| Walter Reiher Ph.D. | Chief Information Officer | – |
| Jan Smith Ph.D. | Chief Scientific Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.